Our experts are attending the 3rd Nasal Formulation & Delivery Summit in Boston, MA (1-3 April 2025). Connect with our team to learn how we can help you to overcome the challenges of complex drug product development.

During the 3rd Nasal Formulation & Delivery Summit 2025 in Boston, you can connect with our experts and learn how our scientists provide development support for a wide range of pharmaceutical dosage forms. 

Our specialist expertise in orally inhaled and nasal drug development is integrated with formulation and testing services for both small molecules and biologics. Our teams carry out early-stage pre-formulation support, solubility screening, drug-excipient compatibility, stability testing, extractables and leachables testing and device selection support.

The nasal formulation & delivery event is also an opportunity to discuss with experts the latest innovations for biopharmaceutical development. For inhaled biologic development, we provide comprehensive protein characterisation services which are supported by forced degradation and stability monitoring for the protein’s structure and bioactivity throughout formulation and storage. Interaction with the delivery device and closure systems are evaluated through comprehensive extractable and leachable testing and toxicological assessments. Reach out to our team now to find out more.

CONFERENCE RESOURCES:  
BROCHURE: Inhaled or Nasal Biologic Drug Development 
BROCHURE: Intertek Pharmaceutical Services
BROCHURE: Stability Testing and Storage Capabilities 
BROCHURE: Intertek Inhaled Product Development Brochure

DOWNLOADS:

Learn more about the Conference

With over 30 years of experience in supporting our clients’ inhaled and nasal product developments, we deliver world-class support to help you meet the challenges of your demanding development programs. The Intertek Melbourn laboratory is inspected and approved by the UK Medicines & Healthcare Products Regulatory Agency (MHRA) for GMP compliance. The Laboratory has also been inspected by the US Food and Drug Administration (FDA) against GMP as part of clients’ pre-approval inspections.

 

Need help or have a question?

Related Links

Contact Intertek